Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Othus M., Thomas I., Wang X., Ariti C., Mehta P., Sydenham M., Hills RK., Burnett AK., Nand S., Assouline S., Michaelis LC., Erba HP., Russell N., Kerr KF., Walter RB., Dennis M.